Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2013

01-10-2013 | Research Article

Lack of association of genetic polymorphisms of angiotensin converting enzyme 1 and angiotensin II type 1 receptor with breast cancer risk in Iranian population

Authors: Soha Namazi, Ahmad Monabati, Shirin Ardeshir-Rouhani-Fard, Negar Azarpira

Published in: Tumor Biology | Issue 5/2013

Login to get access

Abstract

We aimed to investigate the association of insertion/deletion (I/D) and A1166C polymorphisms of angiotensin I converting enzyme 1 and angiotensin II type 1 receptor genes, respectively and their combination on breast cancer risk in an Iranian population. A case–control study (70 cases, 70 controls) was performed on an Iranian population. The I/D and A1166C polymorphisms were analyzed by polymerase chain reaction (PCR) and restriction fragment length polymorphism PCR, respectively. The results revealed no significant difference between cases and controls in I/D (p = 0.14) and A1166C (p = 0.94) polymorphisms after adjustment for breast cancer known risk factors. In combined genotype analysis, considering DD and AA genotypes as low-risk genotypes, women with one and two high-risk genotypes (one high-risk genotype: adjusted odds ratio (OR), 1.24; two high-risk genotypes: adjusted OR, 1.97) were at higher risk for breast cancer. Also, the highest risk for breast cancer was seen in a subgroup of postmenopausal women carriers of two high-risk genotypes (adjusted OR, 2.41). In conclusion, I/D and A1166C polymorphisms are not significantly associated with breast cancer risk in the Iranian population; however, the combination of these two polymorphisms seems to have a synergic effect on the risk of breast cancer particularly in postmenopausal women, which may deserve consideration in large-scale case–control studies.
Literature
1.
Harirchi I, Kolahdoozan S, Karbakhsh M, Chegini N, Mohseni SM, Montazeri A, et al. Twenty years of breast cancer in Iran: downstaging without a formal screening program. Ann Oncol. 2011;22:93–7.CrossRefPubMed
2.
Paul M, Mehr AP, Kreutz R. Physiology of local renin–angiotensin systems. Physiol Rev. 2006;86:747–803.CrossRefPubMed
3.
Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis. 2008;29:1675–84.CrossRefPubMed
4.
Rosenthal T, Gavras I. Angiotensin inhibition and malignancies: a review. J Hum Hypertens. 2009;23:623–35.CrossRefPubMed
5.
Sayed-Tabatabaei FA, Oostra BA, Isaacs A, Van Duijn CM, Witteman JCM. ACE polymorphisms. Circ Res. 2006;98:1123–33.CrossRefPubMed
6.
Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343–6.PubMedCentralCrossRefPubMed
7.
Haiman CA, Henderson SO, Bretsky P, Kolonel LN, Henderson BE. Genetic variation in angiotensin I-converting enzyme (ACE) and breast cancer risk: the multiethnic cohort. Cancer Res. 2003;63:6984–7.PubMed
8.
Alves Corrêa SA, Ribeiro de Noronha SM, Nogueira-de-Souza NC, Valleta de Carvalho C, Massad Costa AM, Juvenal Linhares J et al. Association between the angiotensin-converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms and breast cancer among Brazilian women. J Renin Angiotensin Aldosterone Syst. 2009;10:51–8
9.
Koh WP, Yuan JM, Sun CL, Van den Berg D, Seow A, Lee HP, et al. Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res. 2003;63:573–8.PubMed
10.
González-Zuloeta Ladd AM, Vasquez AA, Sayed-Tabatabaei FA, Coebergh JW, Hofman A, Njajou O, et al. Angiotensin-converting enzyme gene insertion/deletion polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14:2143–6.CrossRefPubMed
11.
Van Der Knaap R, Siemes C, Coebergh JW, Van Duijn CM, Hofman A, Stricker BHC. Renin–angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: The Rotterdam study. Cancer. 2008;112:748–57.CrossRefPubMed
12.
Oro C, Qian H, Thomas WG. Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. Pharmacol Ther. 2007;113:210–26.CrossRefPubMed
13.
Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res. 2002;53:672–7.CrossRefPubMed
14.
Wassmann S, Nickenig G. Pathophysiological regulation of the AT1-receptor and implications for vascular disease. J Hypertens. 2006;24:S15–21.CrossRef
15.
Komukai K, Mochizuki S, Yoshimura M. Gender and the renin–angiotensin–aldosterone system. Fundam Clin Pharmacol. 2010;24:687–98.CrossRefPubMed
16.
Afonso N. Women at high risk for breast cancer—what the primary care provider needs to know. J Am Board Fam Med. 2009;22:43–50.CrossRefPubMed
17.
Lorincz A, Sukumar S. Molecular links between obesity and breast cancer. Endocr Relat Cancer. 2006;13:279–92.CrossRefPubMed
18.
Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002;3:565–74.CrossRefPubMed
19.
Namazi S, Monabati A, Ardeshir-Rouhani-Fard S, Azarpira N. Association of angiotensin I converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms with breast cancer prognostic factors in iranian population. Mol Carcinog. 2010;49:1022–30.CrossRefPubMed
20.
Koh WP, Yuan JM, Van Den Berg D, Lee HP, Yu MC. Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore. Carcinogenesis. 2005;26:459–64.CrossRefPubMed
21.
Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR. Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65–79 years. Cancer. 2003;98:1504–13.CrossRefPubMed
22.
Welsh ML, Buist DSM, Aiello Bowles EJ, Anderson ML, Elmore JG, Li CI. Population-based estimates of the relation between breast cancer risk, tumor subtype, and family history. Breast Cancer Res Treat. 2009;114:549–58.PubMedCentralCrossRefPubMed
23.
Dumitrescu RG, Cotarla I. Understanding breast cancer risk—where do we stand in 2005? J Cell Mol Med. 2005;9:208–21.CrossRefPubMed
24.
Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993;15:17–30.PubMed
25.
Biller H, Zissel G, Ruprecth B, Nauck M, Busse Grawitz A, Müller-Quernheim J. Genotype-corrected reference values for serum angiotensin-converting enzyme. Eur Respir J. 2006;28:1085–90.CrossRefPubMed
26.
Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992;51:197–205.PubMedCentralPubMed
27.
Castellon R, Hamdi HK. Demystifying the ACE polymorphism: from genetics to biology. Curr Pharm Des. 2007;13:1191–8.CrossRefPubMed
28.
Baudin B. New aspects on angiotensin-converting enzyme: from gene to disease. Clin Chem Lab Med. 2002;40:256–65.CrossRefPubMed
29.
Ceolotto G, Papparella I, Bortoluzzi A, Strapazzon G, Ragazzo F, Bratti P, et al. Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives. Am J Hypertens. 2011;24:241–6.CrossRefPubMed
30.
Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer. Trends Endocrinol Metab. 2005;16:293–9.CrossRefPubMed
31.
Rhodes D, Ateeq B, Cao Q, Tomlins S, Mehra R, Laxman B, et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci U S A. 2009;106:10284–9.PubMedCentralCrossRefPubMed
32.
Tiret L, Bonnardeaux A, Poirier O, Ricard S, Marques-Vidal P, Evans A, et al. Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet. 1994;344:910–3.CrossRefPubMed
33.
Fukazawa R, Sonobe T, Hamamoto K, Hamaoka K, Sakata K, Asano T, et al. Possible synergic effect of angiotensin-I converting enzyme gene insertion/deletion polymorphism and angiotensin-II type-1 receptor 1166A/C gene polymorphism on ischemic heart disease in patients with Kawasaki disease. Pediatr Res. 2004;56:597–601.CrossRefPubMed
34.
Szolnoki Z, Maasz A, Magyari L, Horvatovich K, Farago B, Somogyvari F, et al. Coexistence of angiotensin II type-1 receptor A1166C and angiotensin-converting enzyme D/D polymorphism suggests susceptibility for small-vessel-associated ischemic stroke. Neuromolecular Med. 2006;8:353–60.CrossRefPubMed
35.
Álvarez R, Reguero JR, Batalla A, Iglesias-Cubero G, Cortina A, Álvarez V, et al. Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease. Cardiovasc Res. 1998;40:375–9.CrossRefPubMed
36.
Burger HG. Physiology and endocrinology of the menopause. Medicine (Baltimore). 2006;34:27–30.CrossRef
37.
Dean SA, Tan J, O'Brien ER, Leenen FHH. 17β-Estradiol downregulates tissue angiotensin-converting enzyme and ANG II type 1 receptor in female rats. Am J Physiol Regul Integr Comp Physiol. 2005;288:R759–66.CrossRefPubMed
38.
Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res. 2002;53:688–708.CrossRefPubMed
Metadata
Title
Lack of association of genetic polymorphisms of angiotensin converting enzyme 1 and angiotensin II type 1 receptor with breast cancer risk in Iranian population
Authors
Soha Namazi
Ahmad Monabati
Shirin Ardeshir-Rouhani-Fard
Negar Azarpira
Publication date
01-10-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0852-6

Other articles of this Issue 5/2013

Tumor Biology 5/2013 Go to the issue

Research Article

Enhanced antitumor efficacy by combination treatment with a human umbilical vein endothelial cell vaccine and a tumor cell lysate-based vaccine

Research Article

Association between NQO1 C609T polymorphism and bladder cancer susceptibility: a systemic review and meta-analysis

Research Article

P53 codon 72 Arg/Pro polymorphism and lung cancer risk in Asians: an updated meta-analysis

Research Article

Polymorphism rs7214723 in CAMKK1 and lung cancer risk in Chinese population

Research Article

Lack of association between vitamin D receptor gene FokI and BsmI polymorphisms and prostate cancer risk: an updated meta-analysis involving 21,756 subjects

Research Article

Expression of CK19 and KIT in resectable pancreatic neuroendocrine tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits